Nglyza(tm) (saxagliptin) With Metformin As Initial Combination Therapy Provided 76-week Long-term Gl

< BACK TO RESEARCH starstarstarstarstar   Science - Research Press Release
27th June 2010, 02:06am - Views: 5460

Business Company Bristol-Myers Squibb And AstraZeneca 2 image



ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combination Therapy Provided 76-Week Long-

Term Glycemic Control In Treatment-Naive Adults With Type 2 Diabetes

ORLANDO, Florida, June 26/PRNewswire-AsiaNet/ --


    - Not for US Media

    Bristol-Myers Squibb Company (NYSE: BMY) 

and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a 

Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy 

with metformin, which produced long-term glycemic improvement [as measured 

by glycosylated hemoglobin level (HbA1c)] in treatment-naive adults with 

type 2 diabetes mellitus inadequately controlled on diet and exercise 

compared to treatment with an investigational 10 mg dose of saxagliptin or 

metformin alone. The study results also demonstrated that a higher number of 

patients were able to achieve the American Diabetes Association recommended 

HbA1c target of less than 7% with ONGLYZA and metformin as initial 

combination therapy, compared to monotherapy of either treatment at week 

76. The initial combination of ONGLYZA and metformin, with or without 

pioglitazone rescue therapy, had similar adverse event (AE) rates compared 

to treatment with investigational saxagliptin or metformin alone.

Results were presented at the 70th American Diabetes Association (ADA) Annual

Scientific Sessions.

    "As type 2 diabetes is a disease that needs to be actively managed,

effective treatment options are needed to help improve blood sugar levels,"

said Andreas Pfutzner, MD, Chief Executive Officer, Institute for Clinical

Research and Development, Mainz, Germany. "These data show that at 76 weeks,

ONGLYZA and metformin when given as an initial treatment provided improved

HbA1c levels for adult patients with type 2 diabetes."

    ONGLYZA has been submitted for regulatory review in more than 58

countries and is approved in 43 countries, including the United States,

Canada, Mexico, 30 EU countries, Chile, India, Brazil, Argentina and

Switzerland. ONGLYZA was approved by the FDA in July 2009 and is indicated as

an adjunct to diet and exercise to improve blood sugar (glycemic) control in

adults for the treatment of type 2 diabetes mellitus. ONGLYZA once daily used

in combination with commonly prescribed oral anti-diabetic medications -

metformin, glyburide (a sulfonylurea) or a thiazolidinedione (TZD),

(pioglitazone or rosiglitazone) - or as a monotherapy statistically

significantly reduced HbA1c levels. ONGLYZA should not be used for the

treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis

(high levels of certain acids, known as ketones, in the blood or urine).

ONGLYZA (saxagliptin) has not been studied in combination with insulin.

    About the Study: Saxagliptin In Combination with Metformin up to 76 Weeks

    The objectives of the study were to assess the long-term efficacy and

tolerability of ONGLYZA plus metformin and an investigational dose of

saxagliptin plus metformin as initial combination therapy compared to an

investigational dose of saxagliptin or metformin alone. The study assessed

the change from baseline in HbA1c and the proportion of individuals achieving

the American Diabetes Association recommended HbA1c target of less than 7%.

    The study was a multicenter, randomized, double-blind, active-controlled,

24 week short-term study of 1,306 patients followed by a 52 week long-term

extension period, which included 1,103 patients with type 2 diabetes (ages

18-77). Patients were required to be treatment naive and have screening HbA1c 

levels of greater than or equal to 8% and less than or equal to 12% to enter

the study. After a one-week placebo lead-in phase, individuals were

randomized to one of four separate treatment groups: ONGLYZA 5 mg + metformin

500 mg (n=320), an investigational dose of saxagliptin 10 mg + metformin 500

mg (n=323) or saxagliptin 10 mg + placebo (n=335), or metformin 500 mg +

placebo (n=328), given daily. In the treatment groups which included

metformin, the daily metformin dose could be increased to a maximum of 2,000

mg based on pre-specified glycemic criteria. Patients whose HbA1c exceeded

predetermined levels during the study period received pioglitazone therapy

and were eligible to enter directly into the long-term extension period.

    Study Results

    A total of 1,240 patients, including 612 who remained in the study

without requiring rescue therapy through week 76, were included in a repeated

measures analysis of HbA1c change from baseline. After 76 weeks, individuals

in the ONGLYZA + metformin treatment groups demonstrated a greater adjusted

mean change in HbA1c from baseline: -2.31% for ONGLYZA 5 mg + metformin group

(n=303; baseline HbA1c 9.41%) and -2.33% for investigational saxagliptin 10

mg + metformin group (n= 313; baseline HbA1c 9.54%), compared to -1.55% for

saxagliptin 10 mg + placebo (n= 316; baseline HbA1c 9.61%) and -1.79% for

metformin + placebo (n= 308; baseline HbA1c 9.42%).

    A greater percentage of individuals treated with ONGLYZA (saxagliptin) in

combination with metformin achieved HbA1c of less than 7% after 76 weeks:

51.1% for ONGLYZA 5 mg + metformin and 50.8% in the investigational

saxagliptin 10 mg + metformin, compared to 25.0% for saxagliptin 10 mg +

placebo and 34.7% for metformin + placebo.

    No attenuation of the reduction in three-hour postprandial glucose OGTT

(oral glucose tolerance test) as measured by the area under the curve was

apparent between weeks 24 and 76 for the ONGLYZA + metformin groups; partial

attenuation did occur in both monotherapy groups. The overall proportion of

individuals requiring rescue or discontinuation for lack of efficacy by week

76 was lower in the ONGLYZA 5 mg + metformin group (23.1%) and

investigational saxagliptin 10 mg + metformin group (26.0%) versus the

saxagliptin 10 mg + placebo (47.2%) and metformin + placebo (34.1%) groups of

the study.

    The percentage of patients with reported adverse events was similar

across all treatment groups. Adverse event rates were as follows: 65.9% for

ONGLYZA 5 mg + metformin, 68.4% for investigational saxagliptin 10 mg +

metformin, 66.3% for saxagliptin 10 mg + placebo, 68.3% for metformin +


    The occurrence of confirmed hypoglycemia (symptoms of hypoglycemia with a

fingerstick glucose less than or equal to 50 mg/dL) was: three cases (0.9 %)

in the investigational saxagliptin 10 mg + metformin group and two cases

(0.6%) in the metformin + placebo group, with no cases of confirmed

hypoglycemia in the ONGLYZA 5 mg + metformin or the saxagliptin 10 mg +

placebo groups.


Business Company Bristol-Myers Squibb And AstraZeneca 3 image

    Indication and Important Limitations of Use

    ONGLYZA is indicated as an adjunct to diet and exercise to improve

glycemic control in adults with type 2 diabetes mellitus.

    ONGLYZA should not be used for the treatment of type 1 diabetes mellitus

or diabetic ketoacidosis.

    ONGLYZA (saxagliptin) has not been studied in combination with insulin.

    Important Safety Information


    - Use with Medications Known to Cause Hypoglycemia: Insulin

secretagogues, such as sulfonylureas, cause hypoglycemia. Therefore, a

lower dose of the insulin secretagogue may be required to reduce the risk

of hypoglycemia when used in combination with ONGLYZA.

    - Macrovascular Outcomes: There have been no clinical studies

establishing conclusive evidence of macrovascular risk reduction with

ONGLYZA or any other antidiabetic drug.

    Most common adverse reactions (regardless of investigator assessment of

causality) reported in greater than or equal to 5% of patients treated with 

ONGLYZA and more commonly than in patients treated with control were upper 

respiratory tract infection (7.7%, 7.6%), headache (7.5%, 5.2%), 

nasopharyngitis (6.9%, 4.0%) and urinary tract infection (6.8%, 6.1%). 

When used as add-on combination therapy with a thiazolidinedione, the 

incidence of peripheral edema for ONGLYZA 2.5 mg, 5 mg, and placebo was 

3.1%, 8.1% and 4.3%, respectively.

    Laboratory Tests: There was a dose-related mean decrease in absolute

lymphocyte count observed with ONGLYZA.

    Drug Interactions: Because ketoconazole, a strong CYP3A4/5

inhibitor, increased saxagliptin exposure, the dose of ONGLYZA should be

limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor (e.g.,

atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole,

nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin).

    Patients with Renal Impairment: The dose of ONGLYZA is 2.5 mg

once daily for patients with moderate or severe renal impairment, or with

end-stage renal disease requiring hemodialysis (creatinine clearance [CrCl]

less than or equal to 50 mL/min). ONGLYZA (saxagliptin) should be 

administered following hemodialysis. ONGLYZA has not been studied in patients 

undergoing peritoneal dialysis. Assessment of renal function is recommended 

prior to initiation of ONGLYZA and periodically thereafter.

    Pregnant and Nursing Women: There are no adequate and well-controlled 

studies in pregnant women. ONGLYZA, like other antidiabetic medications, 

should be used during pregnancy only if clearly needed. It is not known 

whether saxagliptin is secreted in human milk. Because many drugs are 

secreted in human milk, caution should be exercised when ONGLYZA is

administered to a nursing woman.

    Pediatric Patients: Safety and effectiveness of ONGLYZA in

pediatric patients have not been established.

    Bristol-Myers Squibb and AstraZeneca Collaboration

Business Company Bristol-Myers Squibb And AstraZeneca 4 image

    Bristol-Myers Squibb and AstraZeneca entered into a collaboration in

January 2007 to enable the companies to research, develop and commercialize

select investigational drugs for type 2 diabetes. The Bristol-Myers

Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient

care, improving patient outcomes and creating a new vision for the treatment

of type 2 diabetes.

    About Bristol-Myers Squibb

    Bristol-Myers Squibb is a global biopharmaceutical company whose mission

is to discover, develop and deliver innovative medicines that help patients

prevail over serious diseases. For more information about Bristol-Myers

Squibb, visit or follow us on Twitter at

    About AstraZeneca

    AstraZeneca is a global, innovation-driven biopharmaceutical business

with a primary focus on the discovery, development and commercialization of

prescription medicines. As a leader in gastrointestinal, cardiovascular,

neuroscience, respiratory and inflammation, oncology and infectious disease

medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In

the United States, AstraZeneca is a $14.8 billion healthcare business.

    For more information about AstraZeneca in the US or our AZ&Me(TM)

Prescription Savings programs, please visit: or call 

1-800-AZandMe (292-6363).

    ONGLYZA is a trademark of the Bristol-Myers Squibb Company.

    SOURCE: Bristol-Myers Squibb and AstraZeneca

AsiaNet releases please visit

news articles logo NEWS ARTICLES
Contact News Articles |Remove this article